Explore

Program Map

Start with a treatment, device, company, diagnosis, or trial ID. Each record keeps the source trail close to the claim.

161Main(26 active)

148Status checked

135Strong

320Backlog

More filters and sort (1 active)

Company-led only

26 records in Main database · 18 strong · 18 status checked

Compare	Program	Company / Sponsor	Type	Product	Modality	Stage	Status	Reliability	Evidence	Conf.	Population	Indications
Add	AK-OTOF by Eli Lilly and Akouos	Eli Lilly and Company	Therapeutic	-	Gene Therapy	Phase 2	Active	Details checkedStrong evidence	trial · Priority 1	95%	PediatricAdult+6	Hearing LossSensorineural Hearing Loss+3
Add	SENS-401 (Arazasetron) by Sensorion	Sensorion	Therapeutic	-	Small Molecule	Phase 2	Active	Details checkedStrong evidence	company · Priority 1	94%	AdultSudden / SSNHL+2	Hearing LossSensorineural Hearing Loss+2
Add	SENS-501 by Sensorion	Sensorion	Therapeutic	-	Gene Therapy	Phase 1/2	Active	Details checkedStrong evidence	trial · Priority 1	94%	PediatricCongenital+5	Hearing LossSensorineural Hearing Loss+3
Add	Envoy Medical Acclaim Cochlear Implant	Envoy Medical	Device	Cochlear Implants	Cochlear/Auditory Implant	Phase 2/3	Active	Details checkedStrong evidence	trial · Priority 1	93%	AdultPost-Lingual+1	Hearing LossSensorineural Hearing Loss
Add	Rincell-1 by Rinri Therapeutics	Rinri Therapeutics	Therapeutic	-	Cell Therapy	Phase 1/2	Active	Details checkedStrong evidence	trial · Priority 1	92%	AdultAge-Related+1	Hearing LossSensorineural Hearing Loss+2
Add	AC102 by AudioCure Pharma	AudioCure Pharma	Therapeutic	-	Small Molecule	Phase 2	Active	Details checkedStrong evidence	trial · Priority 1	91%	AdultSudden / SSNHL+1	Hearing LossSensorineural Hearing Loss+2
Add	Auricle Tinnitus Device	Auricle Inc.	Device	Tinnitus Neuromodulation	Neuromodulation	Phase 2	Active	Details checkedStrong evidence	company · Priority 1	90%	AdultTinnitus	Tinnitus
Add	SPI-1005 by Sound Pharmaceuticals	Sound Pharmaceuticals	Therapeutic	-	Small Molecule	Phase 3	Active	Details checkedStrong evidence	trial · Priority 1	90%	AdultNoise-Induced+2	Hearing LossSensorineural Hearing Loss+3
Add	ACOU085 by Acousia Therapeutics	Acousia Therapeutics GmbH	Therapeutic	-	Small Molecule	Phase 2	Active	Details checkedStrong evidence	company · Priority 2	93%	AdultAge-Related+1	Hearing LossSensorineural Hearing Loss+2
Add	CIL001 (Paliroden) by Cilcare	Cilcare SAS	Therapeutic	-	Small Molecule	Phase 1/2	Active	Details checkedStrong evidence	trial · Priority 2	92%	AdultDiabetes+2	Hearing LossSensorineural Hearing Loss+2
Add	NS101 by Neuracle Science	Neuracle Science Co., Ltd.	Therapeutic	-	Biologic	Phase 1/2	Active	Details checkedStrong evidence	trial · Priority 2	92%	AdultSudden / SSNHL+2	Hearing LossSensorineural Hearing Loss+2
Add	AK-antiVEGF by Eli Lilly and Akouos	Eli Lilly and Company	Therapeutic	-	Gene Therapy	Phase 1/2	Active	Details checkedStrong evidence	trial · Priority 2	90%	AdultUnilateral+2	Vestibular SchwannomaHearing Loss
Add	Precision Neuroscience Layer 7 Cortical Interface	Precision Neuroscience	Software/Neurotech	Auditory BCI / Neurotech	BCI/Neurotech	Approved	Active	Details checkedStrong evidence	regulatory · Priority 2	90%	AdultImplantable Bci+4	Communication ImpairmentSevere Paralysis+1
Add	Paradromics Connexus BCI	Paradromics	Software/Neurotech	Auditory BCI / Neurotech	BCI/Neurotech	Interventional/NA	Active	Details checkedStrong evidence	company · Priority 2	89%	AdultImplantable Bci+4	Communication ImpairmentSevere Paralysis+2
Add	GJB2-GT by Sensorion	Sensorion	Therapeutic	-	Gene Therapy	Preclinical	Active	Details checkedStrong evidence	company · Priority 2	88%	CongenitalGenetic+1	Hearing LossSensorineural Hearing Loss+1
Add	ONWARD ARC-BCI / DigitalBridge	ONWARD Medical	Software/Neurotech	Auditory BCI / Neurotech	BCI/Neurotech	Interventional/NA	Active	Details checkedStrong evidence	publication · Priority 2	88%	AdultImplantable Bci+4	Severe ParalysisCommunication Impairment
Add	ReSonance by Lineage Cell Therapeutics	Lineage Cell Therapeutics	Therapeutic	-	Cell Therapy	Preclinical	Active	Details checkedStrong evidence	company · Priority 2	87%	AdultAuditory Neuropathy	Hearing LossSensorineural Hearing Loss+1
Add	AOK-1	Boehringer Ingelheim	Therapeutic	-	Regenerative Medicine	Preclinical	Active	Details checkedStrong evidence	company · Priority 2	82%	AdultAge-Related+1	Hearing LossSensorineural Hearing Loss+2
Add	Synchron Stentrode / SWITCH BCI	Synchron	Software/Neurotech	Auditory BCI / Neurotech	BCI/Neurotech	Interventional/NA	Active	Details checkedClinical trial listing only	registry+publication+company · Priority 2	92%	AdultImplantable Bci+4	Communication ImpairmentSevere Paralysis+2
Add	Neuralink N1 Implant / Telepathy	Neuralink	Software/Neurotech	Auditory BCI / Neurotech	BCI/Neurotech	Interventional/NA	Active	Details checkedClinical trial listing only	registry+company · Priority 2	91%	AdultImplantable Bci+4	Communication ImpairmentSevere Paralysis+2
Add	EHT102 by EuHearing	Shanghai EuHearing Therapeutics Co., Ltd	Therapeutic	-	Gene Therapy	Phase 1/2	Active	Details checkedClinical trial listing only	trial · Priority 2	90%	PediatricGenetic+3	Hearing LossSensorineural Hearing Loss+3
Add	BrainGate2 Neural Interface System	BrainGate ConsortiumSponsor	Software/Neurotech	Auditory BCI / Neurotech	BCI/Neurotech	Interventional/NA	Active	Details checkedClinical trial listing only	registry+institution · Priority 2	88%	AdultImplantable Bci+4	Communication ImpairmentSevere Paralysis+2
Add	Isosorbide Oral Solution by Lunan Better Pharmaceutical	Lunan Better Pharmaceutical Co., Ltd.	Therapeutic	-	Small Molecule	Phase 2/3	Active	Details checkedClinical trial listing only	trial · Priority 2	88%	AdultUnilateral+1	Hearing LossTinnitus
Add	WHO hearWHO Hearing Screener	World Health OrganizationSponsor	Diagnostic	Diagnostics	Diagnostic	Marketed	Active	Details checkedClinical trial listing only	publication · Priority 2	88%	AdultScreening+2	Hearing LossNoise-Induced Hearing Loss+1
Add	Cochlear CI632D dexamethasone-eluting electrode array	Cochlear	Device	Cochlear Implants	Cochlear/Auditory Implant	Interventional/NA	Active	Details checkedClinical trial listing only	registry · Priority 2	86%	AdultSensorineural+2	Hearing LossSensorineural Hearing Loss
Add	OHSU/Oricula ORC-13661 amikacin otoprotection study	Investigator-led studySponsor	Therapeutic	-	Small Molecule	Phase 2	Active	Details checkedClinical trial listing only	registry · Priority 2	83%	AdultOtotoxicity+3	Hearing LossOtotoxicity+1

AK-OTOF by Eli Lilly and Akouos

Eli Lilly and Company · Gene Therapy · Phase 2

ActiveTherapeuticStronger sources

Evidence

trial

Confidence

95%

Indications

Hearing LossSensorineural Hearing LossGenetic Hearing LossOTOF-Related Hearing Loss

Population

PediatricAdultCongenitalGenetic

Details

SENS-401 (Arazasetron) by Sensorion

Sensorion · Small Molecule · Phase 2

ActiveTherapeuticStronger sources

Evidence

company

Confidence

94%

Indications

Hearing LossSensorineural Hearing LossSudden Sensorineural Hearing LossCisplatin-Induced Hearing Loss

Population

AdultSudden / SSNHLCisplatin OtotoxicityCochlear Implant

Details

SENS-501 by Sensorion

Sensorion · Gene Therapy · Phase 1/2

ActiveTherapeuticStronger sources

Evidence

trial

Confidence

94%

Indications

Hearing LossSensorineural Hearing LossGenetic Hearing LossOTOF-Related Hearing Loss

Population

PediatricCongenitalGeneticOTOF / DFNB9

Details

Envoy Medical Acclaim Cochlear Implant

Envoy Medical · Cochlear/Auditory Implant · Phase 2/3

ActiveDeviceCochlear ImplantsStronger sources

Evidence

trial

Confidence

93%

Indications

Hearing LossSensorineural Hearing Loss

Population

AdultPost-LingualProfound

Details

Rincell-1 by Rinri Therapeutics

Rinri Therapeutics · Cell Therapy · Phase 1/2

ActiveTherapeuticStronger sources

Evidence

trial

Confidence

92%

Indications

Hearing LossSensorineural Hearing LossAge-Related Hearing LossAuditory Neuropathy

Population

AdultAge-RelatedAuditory Neuropathy

Details

AC102 by AudioCure Pharma

AudioCure Pharma · Small Molecule · Phase 2

ActiveTherapeuticStronger sources

Evidence

trial

Confidence

91%

Indications

Hearing LossSensorineural Hearing LossSudden Sensorineural Hearing LossTinnitus

Population

AdultSudden / SSNHLTinnitus

Details

Auricle Tinnitus Device

Auricle Inc. · Neuromodulation · Phase 2

ActiveDeviceTinnitus NeuromodulationStronger sources

Evidence

company

Confidence

90%

Indications

Tinnitus

Population

AdultTinnitus

Details

SPI-1005 by Sound Pharmaceuticals

Sound Pharmaceuticals · Small Molecule · Phase 3

ActiveTherapeuticStronger sources

Evidence

trial

Confidence

90%

Indications

Hearing LossSensorineural Hearing LossNoise-Induced Hearing LossTinnitus

Population

AdultNoise-InducedTinnitusCisplatin Ototoxicity

Details

ACOU085 by Acousia Therapeutics

Acousia Therapeutics GmbH · Small Molecule · Phase 2

ActiveTherapeuticStronger sources

Evidence

company

Confidence

93%

Indications

Hearing LossSensorineural Hearing LossAge-Related Hearing LossCisplatin-Induced Hearing Loss

Population

AdultAge-RelatedCisplatin Ototoxicity

Details

CIL001 (Paliroden) by Cilcare

Cilcare SAS · Small Molecule · Phase 1/2

ActiveTherapeuticStronger sources

Evidence

trial

Confidence

92%

Indications

Hearing LossSensorineural Hearing LossHidden Hearing LossCochlear Synaptopathy

Population

AdultDiabetesCochlear SynaptopathyHidden Hearing Loss

Details

NS101 by Neuracle Science

Neuracle Science Co., Ltd. · Biologic · Phase 1/2

ActiveTherapeuticStronger sources

Evidence

trial

Confidence

92%

Indications

Hearing LossSensorineural Hearing LossSudden Sensorineural Hearing LossCochlear Synaptopathy

Population

AdultSudden / SSNHLSensorineuralSalvage Therapy

Details

AK-antiVEGF by Eli Lilly and Akouos

Eli Lilly and Company · Gene Therapy · Phase 1/2

ActiveTherapeuticStronger sources

Evidence

trial

Confidence

90%

Indications

Vestibular SchwannomaHearing Loss

Population

AdultUnilateralVestibular SchwannomaHearing Adjacent

Details

Precision Neuroscience Layer 7 Cortical Interface

Precision Neuroscience · BCI/Neurotech · Approved

ActiveSoftware/NeurotechAuditory BCI / NeurotechStronger sources

Evidence

regulatory

Confidence

90%

Indications

Communication ImpairmentSevere ParalysisSpeech Impairment

Population

AdultImplantable BciCortical Surface InterfaceSpeech Decoding

Details

Paradromics Connexus BCI

Paradromics · BCI/Neurotech · Interventional/NA

ActiveSoftware/NeurotechAuditory BCI / NeurotechStronger sources

Evidence

company

Confidence

89%

Indications

Communication ImpairmentSevere ParalysisALSSpeech Impairment

Population

AdultImplantable BciIntracortical InterfaceSpeech Restoration

Details

GJB2-GT by Sensorion

Sensorion · Gene Therapy · Preclinical

ActiveTherapeuticStronger sources

Evidence

company

Confidence

88%

Indications

Hearing LossSensorineural Hearing LossGenetic Hearing Loss

Population

CongenitalGeneticPre-Lingual

Details

ONWARD ARC-BCI / DigitalBridge

ONWARD Medical · BCI/Neurotech · Interventional/NA

ActiveSoftware/NeurotechAuditory BCI / NeurotechStronger sources

Evidence

publication

Confidence

88%

Indications

Severe ParalysisCommunication Impairment

Population

AdultImplantable BciNeurorestorationAssistive Technology

Details

ReSonance by Lineage Cell Therapeutics

Lineage Cell Therapeutics · Cell Therapy · Preclinical

ActiveTherapeuticStronger sources

Evidence

company

Confidence

87%

Indications

Hearing LossSensorineural Hearing LossAuditory Neuropathy

Population

AdultAuditory Neuropathy

Details

AOK-1

Boehringer Ingelheim · Regenerative Medicine · Preclinical

ActiveTherapeuticStronger sources

Evidence

company

Confidence

82%

Indications

Hearing LossSensorineural Hearing LossAge-Related Hearing LossNoise-Induced Hearing Loss

Population

AdultAge-RelatedNoise-Induced

Details

Synchron Stentrode / SWITCH BCI

Synchron · BCI/Neurotech · Interventional/NA

ActiveSoftware/NeurotechAuditory BCI / Neurotech

Evidence

registry+publication+company

Confidence

92%

Indications

Communication ImpairmentSevere ParalysisALSLocked-In Syndrome

Population

AdultImplantable BciCommunication AccessibilityAssistive Technology

Details

Neuralink N1 Implant / Telepathy

Neuralink · BCI/Neurotech · Interventional/NA

ActiveSoftware/NeurotechAuditory BCI / Neurotech

Evidence

registry+company

Confidence

91%

Indications

Communication ImpairmentSevere ParalysisALSSpeech Impairment

Population

AdultImplantable BciIntracortical InterfaceCommunication Accessibility

Details

EHT102 by EuHearing

Shanghai EuHearing Therapeutics Co., Ltd · Gene Therapy · Phase 1/2

ActiveTherapeutic

Evidence

trial

Confidence

90%

Indications

Hearing LossSensorineural Hearing LossGenetic Hearing LossOTOF-Related Hearing Loss

Population

PediatricGeneticCongenitalOTOF / DFNB9

Details

BrainGate2 Neural Interface System

BrainGate Consortium · BCI/Neurotech · Interventional/NA

ActiveSoftware/NeurotechAuditory BCI / Neurotech

Evidence

registry+institution

Confidence

88%

Indications

Communication ImpairmentSevere ParalysisLocked-In SyndromeSpeech Impairment

Population

AdultImplantable BciIntracortical InterfaceResearch Platform

Details

Isosorbide Oral Solution by Lunan Better Pharmaceutical

Lunan Better Pharmaceutical Co., Ltd. · Small Molecule · Phase 2/3

ActiveTherapeutic

Evidence

trial

Confidence

88%

Indications

Hearing LossTinnitus

Population

AdultUnilateralMeniere Disease

Details

WHO hearWHO Hearing Screener

World Health Organization · Diagnostic · Marketed

ActiveDiagnosticDiagnostics

Evidence

publication

Confidence

88%

Indications

Hearing LossNoise-Induced Hearing LossAge-Related Hearing Loss

Population

AdultScreeningNoise-InducedAge-Related

Details

Cochlear CI632D dexamethasone-eluting electrode array

Cochlear · Cochlear/Auditory Implant · Interventional/NA

ActiveDeviceCochlear Implants

Evidence

registry

Confidence

86%

Indications

Hearing LossSensorineural Hearing Loss

Population

AdultSensorineuralCochlear ImplantImplantable Device

Details

OHSU/Oricula ORC-13661 amikacin otoprotection study

Investigator-led study · Small Molecule · Phase 2

ActiveTherapeutic

Evidence

registry

Confidence

83%

Indications

Hearing LossOtotoxicityAminoglycoside-Induced Hearing Loss

Population

AdultOtotoxicityAmikacinNtm

Details